 |
|
|
| |
Efficacy and Safety of an Acetyl CoA Carboxylase Inhibitor Are Improved in
Combination With PPAR Agonists in a Dyslipidemic Rat Model
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Archana Vijayakumar, Isabel Olson, Ting Wang, David Hollenback, Maria Toteva, James L. Trevaskis, David G. Breckenridge, Jamie Bates - Gilead Sciences, Inc., Foster City, California, USA
References: 1. Harriman G, et al. Proc Natl Acad Sci U S A 2016;113:E1796-805; 2. Harrison S, et al. J Hepatol 2018;68:S583; 3. Lawitz EJ, et al. Clin Gastroenterol Hepatol 2018;16:1983-91; 4. Loomba R, et al. Gastroenterology 2018;155:1463-73; 5. Goedeke L, et al. Hepatology 2018;68:2197-211; 6. Bates J, et al. J Hepatol 2018;68:S399-400; 7. Bergman A, et al. J Hepatol 2018;68:S582; 8. Kim CW, et al. Cell Metab 2017;26:576; 9. Lawitz E, et al. AASLD 2019, poster LP5; 10. Boeckmans J, et al. Cells 2020;9:37.
Acknowledgment: This study was funded by Gilead Sciences, Inc.
|
| |
|
|
|
|
|
